Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Parous and non-parous women who have completed child-bearing (age criteria of \> 35 years-old, and \<50 years-old)~* Currently practicing or willing to practice contraception throughout the duration of the study~* Women with at least one or two fibroids greater than or equal to 3 cm diameter, and less than or equal to 10 cm diameter for subjects in Group 1, and at least one fibroid greater than or equal to 3 cm diameter, and less than or equal to 10 cm diameter for subjects in Group 2~* Fibroids will be intramural fibroids which will be surrounded by a layer of myometrium. Fibroids must be well visualized on ultrasound examination and provide a clear path for injection~* Women who were planning to undergo abdominal hysterectomy or myomectomy for treatment of symptomatic fibroids. Subjects must be willing to defer the operation until 24-96 hours after study treatment for Group 1 and for 60-90 days after study treatment for Group 2. The patients will understand that they may choose to have surgery or any other non-study treatment at any time after enrollment and end study participation~* Typical large fibroids visualized as hypo-intense on a T2-weighted MRI scan~Exclusion Criteria:~* Inability to understand study procedures or to comply with study visits and requirements~* BMI \> 40kg/m2~* History of allergic reaction to study medication (Collagenase Clostridium Histolyticum) or any components of the study drug~* Inability to undergo hysterectomy or myomectomy~* Inability to tolerate MRI and transvaginal ultrasound procedures (i.e. presence of an intra-uterine device (IUD), pacemakers, aneurismal clips or other metallic devices that are not compatible with magnetic resonance imaging). However women with IUD's compatible with MRI are eligible for the study~* Medical problems including: genetic diseases that cause fibroids, history of thromboembolic (blood clot) events or need for anticoagulation (Coumadin, Heparin, etc.) Subjects taking or planning to take anti-coagulant medication (except for ≤ 150 mg aspirin daily) within 7 days administration study drug and within 7 days before and after hysterectomy~* A history of cancer within the past 5 years~* Abnormal liver function tests (typically, will be \>20% elevation). Mild elevations will be at the discretion of the investigators, but undiagnosed liver conditions will represent an exclusion criterion~* Pregnancy or lactation. Pregnancy will be evaluated by urine test every 30 days if necessary. Patients will be asked to use non-hormonal contraception methods while in this study~* Severe anemia (hematocrit \<30). Mild anemia is common in women with fibroids~* Recent rapid growth of fibroids (i.e. doubling in size within one-six months period)~* Any use of agents like Imidazoles, due to possible interference with metabolism~* Unevaluated gynecologic abnormalities (unexplained vaginal bleeding, cervical dysplasia, or abnormal adnexal/ovarian mass)~* Fibroids that are visualized on T2 and T1 weighted MRI as hyperdense or show cystic degeneration~* Inability to undergo injection of fibroid with study drug for any reason, anatomic or other~* Has a known systemic allergy to collagenase or any other excipient of EN3835 or any other procedural medication~* Has, at any time, received collagenase as a treatment~* Is planning to be treated with commercial XIAFLEX at any time during the study~* Type 0 submucosal fibroids, submucosal fibroids with significant protrusion/ pedunculation and subserosal fibroids are not appropriate candidates for the injections

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Saline only (Type: SHAM_COMPARATOR): Injection of saline to assess the injection procedure
- 1.16 mg EN3835 (Type: EXPERIMENTAL): Injection of maximum marketed dose of EN3835 regardless of fibroid size
- Dose 1 (Type: EXPERIMENTAL): Injection of 0.05 mg EN3835 per cm3 fibroid
- Dose 2 (Type: EXPERIMENTAL): Injection of 0.1 mg EN3835 per cm3 fibroid
- Dose 3 (Type: EXPERIMENTAL): Injection of 0.2 mg EN3835 per cm3 fibroid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete